person · Reporting owner

DeFord John A

Disclosed activity across 5 companies

Tapewire entity: 27392
SEC CIK: 0001403373

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
GLOBUS MEDICAL INCGMED · Entity 3496	Director	January 21, 2026	January 23, 2026
MARAVAI LIFESCIENCES HOLDINGS, INC.MRVI · Entity 4291	Director	May 26, 2026	May 28, 2026
NORDSON CORPNDSN · Entity 30	Director	July 31, 2026	August 03, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

GLOBUS MEDICAL INC

Report date January 21, 2026 · Filed January 23, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy Class A Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $94.15 · Expires 2036-01-21	Direct	15,000	Reported balance After 2026-01-21 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-01-21 · Grant · Acquired 15,000 · Balance 15,000 F1: These options were granted on January 21, 2026, and will vest on January 1, 2027.

Filing footnotes · ownership attribution and instrument terms

F1: These options were granted on January 21, 2026, and will vest on January 1, 2027.

MARAVAI LIFESCIENCES HOLDINGS, INC.

Report date May 26, 2026 · Filed May 28, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	205,478	Reported balance After 2026-05-26 transaction · row 1 1 source row Row 1 · 2026-05-26 · Grant · Acquired 46,293 · Balance 205,478 F1: Represents restricted stock units awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan on May 26, 2026, which vest in full upon the earlier of one year from the date of grant or the date of the 2027 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock units awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan on May 26, 2026, which vest in full upon the earlier of one year from the date of grant or the date of the 2027 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.

NORDSON CORP

Report date July 31, 2026 · Filed August 03, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
NDSNSEC Table I · non-derivative	Direct	5,902	Reported balance After 2026-07-31 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-07-31 · Grant · Acquired 84 · Balance 5,902 F1: Pursuant to the terms of the Company's Directors' Deferred Compensation Sub-Plan, the reporting person elected to defer his quarterly cash retainer payment into Stock Equivalent Units. At the time of distribution, stock equivalent units convert to common shares on a one-for-one basis F2: The total holdings include 16 Stock Equivalent Units and/or Restricted Share Units accrued from dividend payments pursuant to the Company's Stock Incentive and Award Plan.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of the Company's Directors' Deferred Compensation Sub-Plan, the reporting person elected to defer his quarterly cash retainer payment into Stock Equivalent Units. At the time of distribution, stock equivalent units convert to common shares on a one-for-one basis

F2: The total holdings include 16 Stock Equivalent Units and/or Restricted Share Units accrued from dividend payments pursuant to the Company's Stock Incentive and Award Plan.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

BARD C R INC /NJ/

Report date December 29, 2017 · Filed January 03, 2018

Section 16 reporting ended · disclosed 2018-01-03. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	30,707.2316	Reported balance After 2017-12-29 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2017-12-29 · Grant · Acquired 13,918 · Balance 30,707.2316 F1: This Form 4 is being filed in connection with the December 29, 2017 closing of the merger (the "Merger") of Lambda Corp. ("Lambda") with and into C. R. Bard, Inc. ("Bard") pursuant to the Agreement and Plan of Merger, dated as of April 23, 2017, among Bard, Becton, Dickinson and Company ("BD") and Lambda. Upon the closing of the Merger, each outstanding share of Bard common stock was converted into the right to receive $222.93 in cash (without interest) and 0.5077 of a share of BD common stock (the "Merger Consideration"). All of the transactions reported in this Form 4 occurred simultaneously upon the closing of the Merger. F2: Includes 13,918 shares of Bard common stock deemed acquired upon satisfaction of performance criteria underlying the award of restricted stock units under the 2012 Long Term Incentive Plan of Bard (as amended and restated) ("PLTIP"). In accordance with the Merger Agreement, these PLTIP units were cancelled in connection with the Merger and converted in accordance with the exchange ratio set forth in the Merger Agreement into equivalent BD PLTIP units.
Common StockSEC Table I · non-derivative	Direct	35,982.2316	Reported balance After 2017-12-29 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2017-12-29 · Grant · Acquired 5,275 · Balance 35,982.2316 F3: Includes 5,275 Bard restricted stock units deemed acquired upon satisfaction of performance goals that were considered achieved upon the closing of the Merger.
Common StockSEC Table I · non-derivative	Direct	35,295	Reported balance After 2017-12-29 transaction · row 3 Account or security details depend on footnotes; rows are not merged. 1 source row Row 3 · 2017-12-29 · Disposition to issuer · Disposed 687.2316 · Balance 35,295 F4: Includes 687.3216 shares of Bard common stock that, upon the closing of the Merger, were cancelled and converted into the right to receive the Merger Consideration.
Common StockSEC Table I · non-derivative	Direct	27,537	Reported balance After 2017-12-29 transaction · row 4 Account or security details depend on footnotes; rows are not merged. 1 source row Row 4 · 2017-12-29 · Disposition to issuer · Disposed 7,758 · Balance 27,537 F5: Includes 7,758 Bard restricted stock units that, upon the closing of the Merger, were assumed by BD and converted in accordance with the exchange ratio set forth in the Merger Agreement into equivalent adjusted BD restricted stock units.
Common StockSEC Table I · non-derivative	Direct	13,918	Reported balance After 2017-12-29 transaction · row 5 Account or security details depend on footnotes; rows are not merged. 1 source row Row 5 · 2017-12-29 · Disposition to issuer · Disposed 13,619 · Balance 13,918 F6: Includes 13,619 shares of restricted stock units acquired through deferral of compensation under Bard's Management Stock Purchase Program ("MSPP"). In accordance with the Merger Agreement (i) each Bard MSPP Unit that by its terms vested and/or became payable at the closing of the Merger was cancelled and converted into, with respect to each share of Bard common stock underlying such Bard MSPP Unit, the right to receive the Merger Consideration; and (ii) each Bard MSPP Unit that did not, by its terms, become payable at the closing of the Merger was assumed and converted in accordance with the exchange ratio set forth in the Merger Agreement into an equivalent adjusted BD MSPP Unit.
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2017-12-29 transaction · row 6 Account or security details depend on footnotes; rows are not merged. 1 source row Row 6 · 2017-12-29 · Disposition to issuer · Disposed 13,918 · Balance 0 F2: Includes 13,918 shares of Bard common stock deemed acquired upon satisfaction of performance criteria underlying the award of restricted stock units under the 2012 Long Term Incentive Plan of Bard (as amended and restated) ("PLTIP"). In accordance with the Merger Agreement, these PLTIP units were cancelled in connection with the Merger and converted in accordance with the exchange ratio set forth in the Merger Agreement into equivalent BD PLTIP units.
Common StockSEC Table I · non-derivative	Indirect401(k) Plan	0	Reported balance After 2017-12-29 transaction · row 7 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 7 · 2017-12-29 · Disposition to issuer · Disposed 83.82 · Balance 0 F7: Includes 83.82 shares of Bard common stock held through the Bard 401(k) Plan that were disposed of upon the closing of the Merger.
Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $186.43 · Expires 2025-12-09	Direct	0	Reported balance After 2017-12-29 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2017-12-29 · Disposition to issuer · Disposed 6,586 · Balance 0 F8: These stock options were assumed by BD and converted in accordance with the exchange ratio set forth in the Merger Agreement into stock appreciation rights with respect to BD common stock.
Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $168.87 · Expires 2024-12-10	Direct	0	Reported balance After 2017-12-29 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2017-12-29 · Disposition to issuer · Disposed 3,768 · Balance 0 F8: These stock options were assumed by BD and converted in accordance with the exchange ratio set forth in the Merger Agreement into stock appreciation rights with respect to BD common stock.
Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $219.56 · Expires 2026-12-14	Direct	0	Reported balance After 2017-12-29 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2017-12-29 · Disposition to issuer · Disposed 8,658 · Balance 0 F8: These stock options were assumed by BD and converted in accordance with the exchange ratio set forth in the Merger Agreement into stock appreciation rights with respect to BD common stock.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 is being filed in connection with the December 29, 2017 closing of the merger (the "Merger") of Lambda Corp. ("Lambda") with and into C. R. Bard, Inc. ("Bard") pursuant to the Agreement and Plan of Merger, dated as of April 23, 2017, among Bard, Becton, Dickinson and Company ("BD") and Lambda. Upon the closing of the Merger, each outstanding share of Bard common stock was converted into the right to receive $222.93 in cash (without interest) and 0.5077 of a share of BD common stock (the "Merger Consideration"). All of the transactions reported in this Form 4 occurred simultaneously upon the closing of the Merger.

F2: Includes 13,918 shares of Bard common stock deemed acquired upon satisfaction of performance criteria underlying the award of restricted stock units under the 2012 Long Term Incentive Plan of Bard (as amended and restated) ("PLTIP"). In accordance with the Merger Agreement, these PLTIP units were cancelled in connection with the Merger and converted in accordance with the exchange ratio set forth in the Merger Agreement into equivalent BD PLTIP units.

F3: Includes 5,275 Bard restricted stock units deemed acquired upon satisfaction of performance goals that were considered achieved upon the closing of the Merger.

F4: Includes 687.3216 shares of Bard common stock that, upon the closing of the Merger, were cancelled and converted into the right to receive the Merger Consideration.

F5: Includes 7,758 Bard restricted stock units that, upon the closing of the Merger, were assumed by BD and converted in accordance with the exchange ratio set forth in the Merger Agreement into equivalent adjusted BD restricted stock units.

F6: Includes 13,619 shares of restricted stock units acquired through deferral of compensation under Bard's Management Stock Purchase Program ("MSPP"). In accordance with the Merger Agreement (i) each Bard MSPP Unit that by its terms vested and/or became payable at the closing of the Merger was cancelled and converted into, with respect to each share of Bard common stock underlying such Bard MSPP Unit, the right to receive the Merger Consideration; and (ii) each Bard MSPP Unit that did not, by its terms, become payable at the closing of the Merger was assumed and converted in accordance with the exchange ratio set forth in the Merger Agreement into an equivalent adjusted BD MSPP Unit.

F7: Includes 83.82 shares of Bard common stock held through the Bard 401(k) Plan that were disposed of upon the closing of the Merger.

F8: These stock options were assumed by BD and converted in accordance with the exchange ratio set forth in the Merger Agreement into stock appreciation rights with respect to BD common stock.

NUVASIVE INC

Report date September 01, 2023 · Filed September 05, 2023

Section 16 reporting ended · disclosed 2023-09-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-09-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-09-01 · Disposition to issuer · Disposed 563 · Balance 0 F1: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F2: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-09-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-09-01 · Disposition to issuer · Disposed 3,230 · Balance 0 F1: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F2: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-09-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-09-01 · Disposition to issuer · Disposed 2,577 · Balance 0 F1: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F2: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-09-01 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-09-01 · Disposition to issuer · Disposed 3,095 · Balance 0 F1: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F2: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-09-01 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-09-01 · Disposition to issuer · Disposed 2,702 · Balance 0 F1: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F2: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-09-01 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2023-09-01 · Disposition to issuer · Disposed 4,816 · Balance 0 F1: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F2: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.
Restricted StockSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-09-01 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2023-09-01 · Disposition to issuer · Disposed 3,788 · Balance 0 F1: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F2: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.

Filing footnotes · ownership attribution and instrument terms

F1: Represented a contingent right to receive one share of the Issuer's common stock upon vesting.

F2: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
July 31, 2026 Filed Aug 3, 2026 13:28 UTC	NORDSON CORP NDSN · Entity 30	GrantNDSN	84	$297.78	$25,013.52	Disclosure SEC source: 0001403373-26-000007 · wk-form4_1785763704.xml · nonDerivative · entry 1 DeFord John A · CIK 0001403373 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,902 F1 · shares: Pursuant to the terms of the Company's Directors' Deferred Compensation Sub-Plan, the reporting person elected to defer his quarterly cash retainer payment into Stock Equivalent Units. At the time of distribution, stock equivalent units convert to common shares on a one-for-one basis F2 · balance_after: The total holdings include 16 Stock Equivalent Units and/or Restricted Share Units accrued from dividend payments pursuant to the Company's Stock Incentive and Award Plan. Read SEC document
May 26, 2026 Filed May 28, 2026 22:20 UTC	MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291	GrantClass A Common Stock	46,293	$0.00	$0.00	Disclosure SEC source: 0001403373-26-000005 · wk-form4_1780006817.xml · nonDerivative · entry 1 DeFord John A · CIK 0001403373 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 205,478 F1 · shares: Represents restricted stock units awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan on May 26, 2026, which vest in full upon the earlier of one year from the date of grant or the date of the 2027 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders. Read SEC document
April 30, 2026 Filed May 4, 2026 13:13 UTC	NORDSON CORP NDSN · Entity 30	GrantNDSN	87	$288.45	$25,095.15	Disclosure SEC source: 0001403373-26-000004 · wk-form4_1777900395.xml · nonDerivative · entry 1 DeFord John A · CIK 0001403373 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,802 F1 · shares: Pursuant to the terms of the Company's Directors' Deferred Compensation Sub-Plan, the reporting person elected to defer his quarterly cash retainer payment into Stock Equivalent Units. At the time of distribution, stock equivalent units convert to common shares on a one-for-one basis F2 · balance_after: The total holdings include 18 Stock Equivalent Units and/or Restricted Share Units accrued from dividend payments pursuant to the Company's Stock Incentive and Award Plan. Read SEC document
January 30, 2026 Filed Feb 3, 2026 15:05 UTC	NORDSON CORP NDSN · Entity 30	GrantNDSN	91	$274.53	$24,982.23	Disclosure SEC source: 0001403373-26-000002 · wk-form4_1770131130.xml · nonDerivative · entry 1 DeFord John A · CIK 0001403373 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,697 F1 · shares: Pursuant to the terms of the Company's Directors' Deferred Compensation Sub-Plan, the reporting person elected to defer his quarterly cash retainer payment into Stock Equivalent Units. At the time of distribution, stock equivalent units convert to common shares on a one-for-one basis. F2 · balance_after: The total holdings include 19 Stock Equivalent Units and/or Restricted Share Units accrued from dividend payments pursuant to the Company's Stock Incentive and Award Plan. Read SEC document
January 21, 2026 Filed Jan 23, 2026 21:49 UTC	GLOBUS MEDICAL INC GMED · Entity 3496	GrantStock Option (Right to Buy Class A Common Stock) · Derivative	15,000	$0.00 Strike: $94.15	$0.00	Disclosure SEC source: 0001193125-26-021195 · ownership.xml · derivative · entry 1 DeFord John A · CIK 0001403373 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Class A Common Stock · 15,000 shares Expires 2036-01-21 F1 · derivative.exercise_date: These options were granted on January 21, 2026, and will vest on January 1, 2027. Read SEC document
November 01, 2025 Filed Nov 3, 2025 18:38 UTC	NORDSON CORP NDSN · Entity 30	GrantNDSN	822	$231.95	$190,662.90	Disclosure SEC source: 0001403373-25-000007 · wk-form4_1762195135.xml · nonDerivative · entry 1 DeFord John A · CIK 0001403373 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,587 F1 · shares: On November 1, 2025, the Company awarded 822 Restricted Share Units an as annual grant to non-employee directors. The units vest in their entirety on October 31, 2026. F2 · balance_after: The total holdings include 71 Stock Equivalent Units and/or Restricted Share Units accrued from dividend payments pursuant to the Company's Stock Incentive and Award Plan. Read SEC document
June 16, 2025 Filed Jun 18, 2025 22:23 UTC	MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291	GrantClass A Common Stock	89,139	$2.16	$192,540.24	Disclosure SEC source: 0001823239-25-000080 · wk-form4_1750285433.xml · nonDerivative · entry 1 DeFord John A · CIK 0001403373 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 159,185 F1 · shares: Represents restricted stock units awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan on June 16, 2025, which vest in full upon the earlier of one year from the date of grant or the date of the 2026 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders. Read SEC document
January 23, 2025 Filed Mar 28, 2025 23:15 UTC	GLOBUS MEDICAL INC GMED · Entity 3496	GrantStock Option (Right to Buy Class A Common Stock) · Derivative	15,000	$0.00 Strike: $92.42	$0.00	Disclosure SEC source: 0000950170-25-047054 · ownership.xml · derivative · entry 1 DeFord John A · CIK 0001403373 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Class A Common Stock · 15,000 shares Expires 2035-01-23 F1 · derivative.exercise_date: These options were granted on January 23, 2025, and will vest on January 1, 2026. Read SEC document
November 12, 2024 Filed Nov 14, 2024 21:32 UTC	MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291	PurchaseClass A Common Stock	17,500	$5.75	$100,625.00	Disclosure SEC source: 0001823239-24-000120 · wk-form4_1731619922.xml · nonDerivative · entry 1 DeFord John A · CIK 0001403373 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,046 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.72 to $5.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. Read SEC document
November 01, 2024 Filed Nov 4, 2024 19:31 UTC	NORDSON CORP NDSN · Entity 30	GrantNDSN	747	$249.03	$186,025.41	Disclosure SEC source: 0000072331-24-000119 · wk-form4_1730748710.xml · nonDerivative · entry 1 DeFord John A · CIK 0001403373 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,694 F1 · shares: On November 1, 2024, the Company awarded 747 Restricted Share Units an as annual grant to non-employee directors. The units vest in their entirety on October 31, 2025. F2 · balance_after: The total holdings include 36 Stock Equivalent Units accrued from dividend payments through participation in the Company's Directors' Deferred Compensation Sub-Plan; 9 Restricted Share Units accrued from dividend payments pursuant to the Company's Stock Incentive and Award Plan; and the addition of 5 shares due to an inadvertent rounding error on fractional shares when calculating prior dividend payments.. Read SEC document
May 23, 2024 Filed May 24, 2024 21:57 UTC	MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291	GrantClass A Common Stock	20,645	$10.78	$222,553.10	Disclosure SEC source: 0001823239-24-000073 · wk-form4_1716587848.xml · nonDerivative · entry 1 DeFord John A · CIK 0001403373 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,546 F1 · shares: Represents restricted stock units granted on May 23, 2024, which vest in full upon the earlier of one year from the date of grant or the date of the 2025 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders. Read SEC document
January 26, 2024 Filed Jan 30, 2024 21:46 UTC	GLOBUS MEDICAL INC GMED · Entity 3496	GrantStock Option (Right to Buy Class A Common Stock) · Derivative	15,000	$0.00 Strike: $53.75	$0.00	Disclosure SEC source: 0000950170-24-008908 · ownership.xml · derivative · entry 1 DeFord John A · CIK 0001403373 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Class A Common Stock · 15,000 shares Expires 2034-01-26 F1 · derivative.exercise_date: These options were granted on January 26, 2024, and will vest on January 1, 2025. Read SEC document
November 01, 2023 Filed Nov 2, 2023 20:33 UTC	NORDSON CORP NDSN · Entity 30	GrantNDSN	749	$211.52	$158,428.48	Disclosure SEC source: 0000072331-23-000183 · wk-form4_1698957211.xml · nonDerivative · entry 2 DeFord John A · CIK 0001403373 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,896 F3 · shares: On November 1, 2023, the Company awarded 749 restricted share units an as annual grant to non-employee directors. The units vest in their entirety on October 31, 2024. Read SEC document
October 31, 2023 Filed Nov 2, 2023 20:33 UTC	NORDSON CORP NDSN · Entity 30	GrantNDSN	105	$212.59	$22,321.95	Disclosure SEC source: 0000072331-23-000183 · wk-form4_1698957211.xml · nonDerivative · entry 1 DeFord John A · CIK 0001403373 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,147 F1 · shares: Stock Equivalent Units accrued through Nordson's Directors' Deferred Compensation Plan. At the time of distributions, stock equivalent units convert to common shares on a one-for-one basis. F2 · balance_after: The total holdings include 6 Share Unit Equivalents accrued from dividend payments through participation in the Company's Deferred Compensation Plans and 2 Restricted Share Units accrued from dividend payments through participation in the Company's Dividend Reinvestment Plan. Read SEC document
September 01, 2023 Filed Sep 5, 2023 16:40 UTC	NUVASIVE INC NUVA · Entity 110002	Disposition to issuerRestricted Stock Unit · Derivative	4,816	$0.00	$0.00	Disclosure SEC source: 0001209191-23-048179 · doc4.xml · derivative · entry 7 DeFord John A · CIK 0001403373 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,816 shares Expires not disclosed F1 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award. F2 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award. Read SEC document
September 01, 2023 Filed Sep 5, 2023 16:40 UTC	NUVASIVE INC NUVA · Entity 110002	Disposition to issuerRestricted Stock · Derivative	3,788	$0.00	$0.00	Disclosure SEC source: 0001209191-23-048179 · doc4.xml · derivative · entry 6 DeFord John A · CIK 0001403373 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,788 shares Expires not disclosed F1 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award. F2 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award. Read SEC document
September 01, 2023 Filed Sep 5, 2023 16:40 UTC	NUVASIVE INC NUVA · Entity 110002	Disposition to issuerRestricted Stock Unit · Derivative	2,702	$0.00	$0.00	Disclosure SEC source: 0001209191-23-048179 · doc4.xml · derivative · entry 5 DeFord John A · CIK 0001403373 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,702 shares Expires not disclosed F1 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award. F2 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award. Read SEC document
September 01, 2023 Filed Sep 5, 2023 16:40 UTC	NUVASIVE INC NUVA · Entity 110002	Disposition to issuerRestricted Stock Unit · Derivative	3,095	$0.00	$0.00	Disclosure SEC source: 0001209191-23-048179 · doc4.xml · derivative · entry 4 DeFord John A · CIK 0001403373 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,095 shares Expires not disclosed F1 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award. F2 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award. Read SEC document
September 01, 2023 Filed Sep 5, 2023 16:40 UTC	NUVASIVE INC NUVA · Entity 110002	Disposition to issuerRestricted Stock Unit · Derivative	2,577	$0.00	$0.00	Disclosure SEC source: 0001209191-23-048179 · doc4.xml · derivative · entry 3 DeFord John A · CIK 0001403373 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,577 shares Expires not disclosed F1 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award. F2 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award. Read SEC document
September 01, 2023 Filed Sep 5, 2023 16:40 UTC	NUVASIVE INC NUVA · Entity 110002	Disposition to issuerRestricted Stock Unit · Derivative	3,230	$0.00	$0.00	Disclosure SEC source: 0001209191-23-048179 · doc4.xml · derivative · entry 2 DeFord John A · CIK 0001403373 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,230 shares Expires not disclosed F1 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award. F2 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award. Read SEC document
September 01, 2023 Filed Sep 5, 2023 16:40 UTC	NUVASIVE INC NUVA · Entity 110002	Disposition to issuerRestricted Stock Unit · Derivative	563	$0.00	$0.00	Disclosure SEC source: 0001209191-23-048179 · doc4.xml · derivative · entry 1 DeFord John A · CIK 0001403373 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 563 shares Expires not disclosed F1 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award. F2 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award. Read SEC document
September 01, 2023 Filed Sep 6, 2023 21:25 UTC Amendment	GLOBUS MEDICAL INC GMED · Entity 3496	GrantStock Option (Right to Buy Class A Common Stock) · Derivative	15,000	$0.00 Strike: $54.23	$0.00	Disclosure SEC source: 0001209191-23-048453 · doc4a.xml · derivative · entry 2 DeFord John A · CIK 0001403373 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Class A Common Stock · 15,000 shares Expires 2033-09-01 F2 · derivative.exercise_date: These options were granted on September 1, 2023, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on September 1, 2024, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months. F3 · derivative.expiration_date: The original Form 4, filed on September 6, 2023, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported an expiration date of September 1, 2024, when in fact such expiration date is September 1, 2033. Read SEC document
September 01, 2023 Filed Sep 6, 2023 21:25 UTC Amendment	GLOBUS MEDICAL INC GMED · Entity 3496	GrantClass A Common Stock	15,578	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-048453 · doc4a.xml · nonDerivative · entry 1 DeFord John A · CIK 0001403373 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,578 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, NuVasive, Inc. ("NuVasive") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into NuVasive (the "Merger"), with NuVasive continuing as a wholly owned subsidiary of the Issuer. At the effective time of the Merger, each NuVasive restricted stock unit award was accelerated, cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Issuer, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of NuVasive common stock underlying such award. Read SEC document
September 01, 2023 Filed Sep 6, 2023 20:48 UTC	GLOBUS MEDICAL INC GMED · Entity 3496	GrantStock Option (Right to Buy Class A Common Stock) · Derivative	15,000	$0.00 Strike: $54.23	$0.00	Disclosure SEC source: 0001209191-23-048412 · doc4.xml · derivative · entry 2 DeFord John A · CIK 0001403373 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Class A Common Stock · 15,000 shares Expires 2024-09-01 F2 · derivative.exercise_date: These options were granted on September 1, 2023, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on September 1, 2024, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months. Read SEC document
September 01, 2023 Filed Sep 6, 2023 20:48 UTC	GLOBUS MEDICAL INC GMED · Entity 3496	GrantClass A Common Stock	15,578	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-048412 · doc4.xml · nonDerivative · entry 1 DeFord John A · CIK 0001403373 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,578 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, NuVasive, Inc. ("NuVasive") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into NuVasive (the "Merger"), with NuVasive continuing as a wholly owned subsidiary of the Issuer. At the effective time of the Merger, each NuVasive restricted stock unit award was accelerated, cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Issuer, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of NuVasive common stock underlying such award. Read SEC document
July 31, 2023 Filed Aug 1, 2023 17:44 UTC	NORDSON CORP NDSN · Entity 30	GrantNDSN	89	$251.61	$22,393.29	Disclosure SEC source: 0000072331-23-000134 · wk-form4_1690911834.xml · nonDerivative · entry 1 DeFord John A · CIK 0001403373 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,034 F1 · shares: Stock Equivalent Units accrued through Nordson's Directors' Deferred Compensation Plan. At the time of distributions, stock equivalent units convert to common shares on a one-for-one basis. F2 · balance_after: The total holdings include 6 shares accrued from dividend payments through participation in the Company's Deferred Compensation Plans and 2 shares accrued from dividend payments through participation in the Company's Dividend Reinvestment Plan. Read SEC document
July 20, 2023 Filed Jul 21, 2023 20:25 UTC	MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291	GrantClass A Common Stock	31,901	$0.00	$0.00	Disclosure SEC source: 0001823239-23-000075 · wf-form4_168997112890875.xml · nonDerivative · entry 1 DeFord John A · CIK 0001403373 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,901 F1 · shares: Represents restricted stock units ("RSUs") awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. Each RSU represents the right to receive one share of Class A Common Stock of the Issuer upon vesting. The RSUs will vest in 1/3rd increments on each of July 20, 2024, July 20, 2025, and July 20, 2026, subject to the Reporting Person's continued service on the Board of Directors of the Issuer. Read SEC document
June 09, 2023 Filed Jun 12, 2023 17:44 UTC	NUVASIVE INC NUVA · Entity 110002	GrantRSUs · Derivative	4,816	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-23-036442 · doc4.xml · derivative · entry 1 DeFord John A · CIK 0001403373 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,816 Underlying: Common Stock · 4,816 shares Expires not disclosed F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2024 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors. F3 · derivative.exercise_date: On February 8, 2023, Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Globus Medical, Inc. ("Globus Medical") and Zebra Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Globus Medical. The Merger Agreement provides, among other things, that subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will merge with and into Issuer (the "Merger"), with Issuer surviving the Merger as a wholly owned subsidiary of Globus Medical. Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each RSU outstanding immediately prior to the Effective Time held by the Reporting Person will fully vest and be cancelled and converted automatically into the right to receive (without interest) 0.75 fully paid and non-assessable shares of Class A common stock of Globus Medical (and cash in lieu of any fractional shares) in respect of each share of Issuer's common stock underlying such RSU. F2 · derivative.expiration_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2024 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors. F3 · derivative.expiration_date: On February 8, 2023, Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Globus Medical, Inc. ("Globus Medical") and Zebra Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Globus Medical. The Merger Agreement provides, among other things, that subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will merge with and into Issuer (the "Merger"), with Issuer surviving the Merger as a wholly owned subsidiary of Globus Medical. Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each RSU outstanding immediately prior to the Effective Time held by the Reporting Person will fully vest and be cancelled and converted automatically into the right to receive (without interest) 0.75 fully paid and non-assessable shares of Class A common stock of Globus Medical (and cash in lieu of any fractional shares) in respect of each share of Issuer's common stock underlying such RSU. Read SEC document
April 28, 2023 Filed May 2, 2023 20:24 UTC	NORDSON CORP NDSN · Entity 30	GrantNDSN	104	$216.31	$22,496.24	Disclosure SEC source: 0000072331-23-000091 · wf-form4_168305906048354.xml · nonDerivative · entry 1 DeFord John A · CIK 0001403373 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,937 F1 · shares: Stock Equivalent Units accrued through Nordson's Directors' Deferred Compensation Plan. At the time of distribution, stock equivalent units convert to common shares on a one-for-one basis. F2 · balance_after: The total holdings include 4 shares accrued from dividend payments through participation in the Company's Deferred Compensation Plans and 11 shares accrued from dividend payments through participation in the Company's Dividend Reinvestment Plan. Read SEC document
January 31, 2023 Filed Feb 2, 2023 19:46 UTC	NORDSON CORP NDSN · Entity 30	GrantNDSN	92	$243.30	$22,383.60	Disclosure SEC source: 0000072331-23-000029 · wf-form4_167536715377176.xml · nonDerivative · entry 1 DeFord John A · CIK 0001403373 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,818 F1 · shares: Stock Equivalent Units accrued through Nordson's Directors' Deferred Compensation Plan. At the time of distributions, stock equivalent units convert to common shares on a one-for-one basis. Read SEC document
November 01, 2022 Filed Nov 2, 2022 19:11 UTC	NORDSON CORP NDSN · Entity 30	GrantNDSN	730	$225.93	$164,928.90	Disclosure SEC source: 0000072331-22-000112 · wf-form4_166741629654448.xml · nonDerivative · entry 2 DeFord John A · CIK 0001403373 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,726 F3 · shares: On November 1, 2022, the Company awarded 730 restricted stock units an as annual grant to non-employee directors, valued at the fourth quarter average stock price of $225.93 per share. Such shares vest on October 31, 2023 unless, with certain exceptions, the reporting person ceases to be a director prior to the vesting date. Read SEC document
October 31, 2022 Filed Nov 2, 2022 19:11 UTC	NORDSON CORP NDSN · Entity 30	GrantNDSN	100	$225.00	$22,500.00	Disclosure SEC source: 0000072331-22-000112 · wf-form4_166741629654448.xml · nonDerivative · entry 1 DeFord John A · CIK 0001403373 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,996 F1 · shares: Stock Equivalent Units accrued through Nordson's Directors' Deferred Compensation Plan. At the time of distribution, stock equivalent units convert to common shares on a one-for-one basis. F2 · balance_after: The total holdings include 3 shares accrued from dividend payments through participation in the Company's Deferred Compensation Plans and 2 shares accrued from dividend payments through participation in the Company's Dividend Reinvestment Plan. Read SEC document
July 29, 2022 Filed Aug 2, 2022 19:39 UTC	NORDSON CORP NDSN · Entity 30	GrantCommon Stock	97	$230.99	$22,406.03	Disclosure SEC source: 0001209191-22-043832 · doc4.xml · nonDerivative · entry 1 DeFord John A · CIK 0001403373 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,891 F1 · shares: Stock Equivalent Units accrued through Nordson's Directors' Deferred Compensation Plan. At the time of distributions, stock equivalent units convert to common shares on a one-for-one basis. F2 · price: The total holdings include 2 shares accrued from dividend payments through participation in the Company's Dividend Reinvestment Plan and 2 shares accrued from dividend payments through participation in the Company's Amended and Restated 2005 Deferred Compensation Plan. Read SEC document
May 11, 2022 Filed May 13, 2022 17:46 UTC	NUVASIVE INC NUVA · Entity 110002	GrantRSUs · Derivative	3,788	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-22-028933 · doc4.xml · derivative · entry 1 DeFord John A · CIK 0001403373 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,788 Underlying: Common Stock · 3,788 shares Expires not disclosed F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2023 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors. F2 · derivative.expiration_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2023 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors. Read SEC document
April 29, 2022 Filed May 2, 2022 17:50 UTC	NORDSON CORP NDSN · Entity 30	GrantCommon Stock	104	$215.69	$22,431.76	Disclosure SEC source: 0001209191-22-026369 · doc4.xml · nonDerivative · entry 1 DeFord John A · CIK 0001403373 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,790 F1 · shares: Stock Equivalent Units accrued through Nordson's Directors' Deferred Compensation Plan. At the time of distributions, stock equivalent units convert to common shares on a one-for-one basis. F2 · balance_after: The total holdings include 4 shares accrued from dividend payments through participation in the Company's Dividend Reinvestment Plan and 4 shares accrued from dividend payments through participation in the Company's Amended and Restated 2005 Deferred Compensation Plan. Read SEC document
January 31, 2022 Filed Feb 1, 2022 15:27 UTC	NORDSON CORP NDSN · Entity 30	GrantCommon Stock	96	$232.54	$22,323.84	Disclosure SEC source: 0001209191-22-005797 · doc4.xml · nonDerivative · entry 1 DeFord John A · CIK 0001403373 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,678 F1 · shares: Stock Equivalent Units accrued through Nordson's Directors' Deferred Compensation Plan. At the time of distributions, stock equivalent units convert to common shares on a one-for-one basis. Read SEC document
November 01, 2021 Filed Nov 2, 2021 20:28 UTC	NORDSON CORP NDSN · Entity 30	GrantCommon Stock	608	$238.43	$144,965.44	Disclosure SEC source: 0001209191-21-062406 · doc4.xml · nonDerivative · entry 2 DeFord John A · CIK 0001403373 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,582 F3 · shares: On November 1, 2021, the Company awarded 608 restricted stock units as an annual grant to non-employee directors, valued at the fourth quarter average stock price of $238.43 per share. Such shares vest on October 31, 2022 unless, with certain exceptions, the reporting person ceases to be a director prior to the vesting date. Read SEC document
October 29, 2021 Filed Nov 2, 2021 20:28 UTC	NORDSON CORP NDSN · Entity 30	GrantCommon Stock	79	$254.21	$20,082.59	Disclosure SEC source: 0001209191-21-062406 · doc4.xml · nonDerivative · entry 1 DeFord John A · CIK 0001403373 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 974 F1 · shares: Stock Equivalent Units accrued through Nordson's Directors' Deferred Compensation Plan. At the time of distribution, stock equivalent units convert to common shares on a one-for-one basis. F2 · balance_after: The total holdings include 4 shares accrued from dividend payments through participation in the Company's Amended and Restated 2005 Deferred Compensation Plan. Read SEC document
July 30, 2021 Filed Aug 3, 2021 19:40 UTC	NORDSON CORP NDSN · Entity 30	GrantCommon Stock	88	$226.13	$19,899.44	Disclosure SEC source: 0001209191-21-049246 · doc4.xml · nonDerivative · entry 1 DeFord John A · CIK 0001403373 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 892 F1 · shares: Stock Equivalent Units accrued through Nordson's Directors' Deferred Compensation Plan. At the time of distributions, stock equivalent units convert to common shares on a one-for-one basis. Read SEC document
May 18, 2021 Filed May 20, 2021 17:45 UTC	NUVASIVE INC NUVA · Entity 110002	GrantRSUs · Derivative	2,702	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-21-034538 · doc4.xml · derivative · entry 1 DeFord John A · CIK 0001403373 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,702 Underlying: Common Stock · 2,702 shares Expires not disclosed F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2022 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors. F2 · derivative.expiration_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2022 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors. Read SEC document
April 30, 2021 Filed May 4, 2021 12:36 UTC	NORDSON CORP NDSN · Entity 30	GrantCommon Stock	94	$211.41	$19,872.54	Disclosure SEC source: 0001209191-21-029661 · doc4.xml · nonDerivative · entry 1 DeFord John A · CIK 0001403373 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 804 F1 · shares: Stock Equivalent Units accrued through Nordson's Directors' Deferred Compensation Plan. At the time of distributions, stock equivalent units convert to common shares on a one-for-one basis. F2 · balance_after: The total holdings include 2 shares accrued from dividend payments through participation in the Company's Dividend Reinvestment Plan and 1 share accrued from dividend payments through participation in the Company's Amended and Restated 2005 Deferred Compensation Plan. Read SEC document
January 29, 2021 Filed Feb 2, 2021 20:31 UTC	NORDSON CORP NDSN · Entity 30	GrantCommon Stock	85	$178.99	$15,214.15	Disclosure SEC source: 0001209191-21-006704 · doc4.xml · nonDerivative · entry 1 DeFord John A · CIK 0001403373 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 707 F1 · shares: Stock Equivalent Units accrued through Nordson's Directors' Deferred Compensation Plan. At the time of distribution, stock equivalent units convert to common shares on a one-for-one basis. Read SEC document
November 23, 2020 Filed Nov 25, 2020 22:06 UTC	NORDSON CORP NDSN · Entity 30	GrantCommon Stock	622	$196.27	$122,079.94	Disclosure SEC source: 0001209191-20-060545 · doc4.xml · nonDerivative · entry 1 DeFord John A · CIK 0001403373 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 622 F1 · shares: On November 23, 2020, the Company awarded 622 restricted share units as an annual grant to the non-employee director, valued at the fourth quarter average stock price of $196.27 per share. Such share units vest on October 31, 2021 unless, with certain exceptions, the reporting person ceases to be a director prior to the vesting date. Read SEC document
May 28, 2020 Filed May 29, 2020 17:44 UTC	NUVASIVE INC NUVA · Entity 110002	GrantRSUs · Derivative	3,095	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-20-032996 · doc4.xml · derivative · entry 1 DeFord John A · CIK 0001403373 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,095 Underlying: Common Stock · 3,095 shares Expires not disclosed F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2021 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors. F2 · derivative.expiration_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2021 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors. Read SEC document
May 09, 2019 Filed May 10, 2019 17:53 UTC	NUVASIVE INC NUVA · Entity 110002	GrantRSUs · Derivative	2,577	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-19-029062 · doc4.xml · derivative · entry 1 DeFord John A · CIK 0001403373 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,577 Underlying: Common Stock · 2,577 shares Expires not disclosed F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2020 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors. F2 · derivative.expiration_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2020 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors. Read SEC document
May 03, 2018 Filed May 7, 2018 18:03 UTC	NUVASIVE INC NUVA · Entity 110002	GrantRSUs · Derivative	3,230	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-18-028414 · doc4.xml · derivative · entry 1 DeFord John A · CIK 0001403373 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,230 Underlying: Common Stock · 3,230 shares Expires not disclosed F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2019 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors. F2 · derivative.expiration_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2019 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors. Read SEC document
February 26, 2018 Filed Feb 28, 2018 18:08 UTC	NUVASIVE INC NUVA · Entity 110002	GrantRSUs · Derivative	563	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-18-014645 · doc4.xml · derivative · entry 1 DeFord John A · CIK 0001403373 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 563 Underlying: Common Stock · 563 shares Expires not disclosed F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on May 3, 2018. F2 · derivative.expiration_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on May 3, 2018. Read SEC document
December 29, 2017 Filed Jan 3, 2018 20:18 UTC	BARD C R INC /NJ/ BCR · Entity 170698	Disposition to issuerOption (Right to Buy) · Derivative	8,658	Not disclosed Strike: $219.56	Not disclosed	Disclosure SEC source: 0001225208-18-000502 · doc4.xml · derivative · entry 10 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,658 shares Expires 2026-12-14 F8 · price: These stock options were assumed by BD and converted in accordance with the exchange ratio set forth in the Merger Agreement into stock appreciation rights with respect to BD common stock. F8 · derivative.exercise_date: These stock options were assumed by BD and converted in accordance with the exchange ratio set forth in the Merger Agreement into stock appreciation rights with respect to BD common stock. Read SEC document
December 29, 2017 Filed Jan 3, 2018 20:18 UTC	BARD C R INC /NJ/ BCR · Entity 170698	Disposition to issuerOption (Right to Buy) · Derivative	3,768	Not disclosed Strike: $168.87	Not disclosed	Disclosure SEC source: 0001225208-18-000502 · doc4.xml · derivative · entry 9 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,768 shares Expires 2024-12-10 F8 · price: These stock options were assumed by BD and converted in accordance with the exchange ratio set forth in the Merger Agreement into stock appreciation rights with respect to BD common stock. F8 · derivative.exercise_date: These stock options were assumed by BD and converted in accordance with the exchange ratio set forth in the Merger Agreement into stock appreciation rights with respect to BD common stock. Read SEC document
December 29, 2017 Filed Jan 3, 2018 20:18 UTC	BARD C R INC /NJ/ BCR · Entity 170698	Disposition to issuerOption (Right to Buy) · Derivative	6,586	Not disclosed Strike: $186.43	Not disclosed	Disclosure SEC source: 0001225208-18-000502 · doc4.xml · derivative · entry 8 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,586 shares Expires 2025-12-09 F8 · price: These stock options were assumed by BD and converted in accordance with the exchange ratio set forth in the Merger Agreement into stock appreciation rights with respect to BD common stock. F8 · derivative.exercise_date: These stock options were assumed by BD and converted in accordance with the exchange ratio set forth in the Merger Agreement into stock appreciation rights with respect to BD common stock. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.